Measurement of anti-CCP antibodies for the diagnosis of rheumatoid arthritis;Medida de los anticuerpos anti-péptido cíclico citrulinado en el diagnóstico de la artritis reumatoide

Quimica Clinica

Volumn 22, Issue 6, 2003, Pages 397-402

  Valladares Gómez, Carmen ^a   Rus Martinez A ^a   Sanchez Molina Acosta M I ^a   Muruzabal Sitges M V ^a   Ibáñez, A Elena ^a   Borque De Larrea, L ^a  

^a HOSPITAL SAN PEDRO   (Spain)

Author keywords

Anti CCP antibodies; Poliarthritis; Rheumatoid arthritis; Rheumatoid factor

Indexed keywords

AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; PEPTIDE ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTHRITIS; ARTICLE; BLOOD DONOR; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; REFERENCE VALUE; RHEUMATOID ARTHRITIS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 1642389981     PISSN: 11392436     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Morrow J, Nelson L, Watts R, Isenberg D. Autoinmune rheumatic disease, 2nd ed. Oxford: Oxford University Press, 1999: 104-146.
2. Kirwan JR. Quilty B prognostic criteria in rheumatoid arthritis: can we predict which patients will require specific anti-rheumatoid treatment?. Clin Exp Rheumatol 1997; 15 Suppl 17: 515-525.
3. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid artritis. Arthritis Rheum 1988; 31: 315-324.
4. Borque L, Linares M, Seco ML, Bellod L, Rus A. Influencia del antígeno en la medida de los factores reumatoides. Quim Clin 2001; 20: 47-52.
5. Smolen JS. Autoantibodies in rheumatoid artritis. In: van Venrooij WJ, Maini RN, editors. Manual of biological markers of disease. Dordrecht (The Netherlands): Kluwer Academic Publishers; 1996. p. C1.1/1-18.
6. Visser H, Gelinck LBS, Kampfraath AH, Breedveld C, Hazes JMW. Diagnostic and prognostic characteristics of the enzyme linked immunosorbent rheumatoid factor assay in rheumatoid arthritis. Ann Rheum Dis 1996; 55: 157-161.
7. Hassfeld W, Steiner G, Graninger W, Witzmann G, Schweitzer H, Smolen JS. Autoantibody to the nuclear antigen RA33; a marker for early rheumatoid arthritis. Br J Rheumatol 1993; 32: 199-203.
8. Lackner KJ, Schlosser U, Lang B, Schmitz G. Autoantibodies against human calpastatin in rheumatoid arthritis: epitope mapping and analysis of patient sera. Br J Rheumatol 1998; 37: 1164-1171.
9. van Boekel MA, Vossenaar ER, van den Hoogen FH, van Venrooij WJ. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 2002; 4: 87-93.
10. Nienhuis RLF, Mandema EA. A new serum factor in patients with rheumatoid arthritis: the antiperinuclear factor. Ann Rheum Dis 1964; 23: 302-305.
11. Young BJ, Mallya RK, Leslie RD, Clark CJ, Hamblin TJ. Antikeratin antibodies in rheumatoid artritis. Br Med J 1979; 2: 97-99.
12. Palosuo T, Lukka M, Alenius H, Kalkkinen N, Aho K, Kurki P, Heikkila R, Nykanen M, von Essen R. Purification of filaggrin from human epidermis and measurement of antifilaggrin autoantibodies in sera from patients with rheumatoid arthritis by an enzyme-linked immunosorbent assay. Int Arch Allergy Immunol 1998; 115: 294-302.
13. Schellekens GA, de Jong BAW, van den Hoogen FHJ, van de Putte LBA, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid artritis-specific autoantibodies. J Clin Invest 1998; 101: 273-281.
14. Sebbag M, Simon M, Vincent C, Masson-Bessiere C, Girbal E, Durieux JJ, et al. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 1995; 95: 2672-2679.
15. Girbal-Neuhauser E, Durieux JJ, Arnaud M, Dalbon P, Sebbag M, Vincent C, Simon M, Senshu T, Masson-Bessiere C, Jolivet-Reynaud C, Jolivet M, Serre G. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol 1999;162: 585-594.
16. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, van Venrooij WJ. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43: 155-163.
17. Kroot E, de Jong BAW, van Leeuwen MA, Swinkels H, van den Hoogen FHJ, van't Hof M, et al. The prognostic value of the anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid artritis. Arthritis Rheum 2000; 43: 1831-1835.
18. van Venrooij WJ, Hazes JM, Visser H. Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med 2002; 60: 383-388.
19. Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS, Steiner G, Rosen A, Zhang C, Menard HA, Zhou ZJ, Palosuo T, Van Venrooij WJ, Wilder RL, Klippel JH, Schumacher HR Jr, El-Gabalawy HS. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000; 2: 236-243.
20. Jansen AL, van der Horst-Bruinsma I, van Schaardenburg D, van de Stadt RJ, de Koning MH, Dijkmans BA. Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol 2002; 29: 2074-2076.
21. Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, Nicaise-Roland P, Sibilia J, Combe B. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003; 62: 120-126.
22. Bas S, Perneger TV, Seitz M, Tiercy JM, Roux-Lombard P, Guerne PA. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology (Oxford) 2002; 41: 809-814.
23. Zweig MH, Campbell G. Receiver-operating characteristics (ROC) plots: a fundamental valuation tool in clinical medicine. Clin Chem 1992; 39: 561-577.
24. Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U, et al. Patients with rheumatois arthritis befit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 1995; 22: 2208-2213.
25. Van der Heide A, Jacobs JWG, Bijlsma JWJ, Heurkens Ah, van Booma-Frankfort C, van der Veen MJ, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs: a randomized, controlled trial. Ann Inter Med 1996; 124: 699-707.
26. Symmons DPM, Jones MA, Scott DL, Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998; 25: 1072-1077.
27. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000; 43: 22-29.
28. Buckland-Wright JC, Clarke GS, Chikanza IC, Grahame R. Quantitative microfocal radiography detects changes in erosion area in patients with early rheumatoid arthritis treated with myocrisine. J Rheumatol 1993; 20: 243-247.
29. Munro R, Hampson R, McEntegart A, Thomson EA, Madhok R, Capell H. Improved functional outcome in patients with early rheumatoid arthritis treated with intamuscular gold: results of a five year prospective study. Ann Rheum Dis 1998; 57: 88-93.
30. Valenstein PN. Evaluating diagnostic tests with imperfect standards. Am J Clin Pathol 1990; 93: 252-258.
31. Visser H, Cessie S, Vos K, Breedveld FC, Hazes JMW. How to diagnose Rheumatoid Arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002; 46: 357-365.
32. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309-318.
33. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-1593.
34. Lipsky PE, van der Heijde DMFM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594-1602.
35. Bizarro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 2001; 47: 1089-1093.